Please visit answersincme.com/MGC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in managing cardiorenal conditions discusses the incorporation of potassium binders into the treatment of hyperkalemia in patients with cardiorenal conditions. Upon completion of this activity, participants should be better able to: Recognize guideline-concordant treatment approaches for hyperkalemia in patients with cardiorenal conditions; Review the clinical profiles of potassium binders approved for the treatment of hyperkalemia in patients with cardiorenal conditions; and Outline management strategies to appropriately incorporate potassium binders into treatment plans for hyperkalemia.

Please visit answersincme.com/CGH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses evidence and guidance on using multimodal approaches for managing patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Upon completion of this activity, participants should be better able to: Identify the continued needs with the currently available therapies for inoperable CTEPH; Review the clinical evidence for multimodal approaches in inoperable CTEPH in the context of currently available therapies; and Outline clinical factors that may facilitate optimal therapeutic selection for patients with inoperable CTEPH.

Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Please visit answersincme.com/PKW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses guideline and treatment updates for the management of hypertrophic cardiomyopathy, and the clinical implications of recent data on novel cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Outline the latest guideline updates for diagnosis and treatment of obstructive HCM; Review strategies to facilitate the early diagnosis of obstructive HCM; and Recognize the clinical significance of the latest data on cardiac myosin inhibitors for the treatment of obstructive HCM.

Please visit answersincme.com/TAR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the integration of perioperative immunotherapy-based regimens for the treatment of resectable non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of neoadjuvant followed by adjuvant immunotherapy-based regimens in patients with resectable NSCLC; Describe current evidence on the use of neoadjuvant plus adjuvant immunotherapy in patients with resectable NSCLC; and Outline practical strategies to integrate neoadjuvant plus adjuvant immunotherapy-based regimens into the treatment plan for appropriate patients with resectable NSCLC.

Please visit answersincme.com/TUD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses the rationale for using novel add-on therapy in patients with pulmonary arterial hypertension (PAH) who are receiving stable background therapy, and the clinical implications of the latest evidence on these add-on therapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of novel add-on therapies in patients with PAH who are receiving stable background therapy; Describe the latest clinical data for novel add-on therapies for patients with PAH who are on stable background therapy; and Outline multidisciplinary strategies for the optimal integration of novel add-on therapies into the existing treatment landscape for patients with PAH, as they become available.

Please visit answersincme.com/TXC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the unmet therapeutic needs in patients with chronic obstructive pulmonary disease (COPD) and the rationale for targeting Type 2 inflammation. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in patients with COPD; Identify patients with COPD who are at high risk of exacerbations despite receiving standard therapies; and Recognize the rationale for targeting Type 2 inflammation for the treatment of COPD.

Please visit answersincme.com/NQF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses current guideline-supported best practices in the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids (OCS) in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.

Please visit answersincme.com/GSN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and thoracic surgery discuss chemo-immunotherapeutic approaches in early-stage non–small cell lung cancer. Upon completion of this activity, participants should be better able to: Review the clinical profiles of available and emerging neoadjuvant and perioperative immunotherapy-based approaches for patients with early-stage NSCLC; Identify patients for whom a neoadjuvant or perioperative immunotherapy-based approach is warranted, based on the available and emerging clinical data; and Outline a multidisciplinary strategy to improve outcomes in early-stage NSCLC through the use of neoadjuvant or perioperative immunotherapy-based approaches in appropriate patients.